Initiating Acalabrutinib After Completion of Pneumocystis jirovecii Pneumonia (PJP) Therapy

1. Minimum Duration and Completion of PJP Treatment

Standard high‑dose trimethoprim‑sulfamethoxazole (TMP‑SMX) should be given for 21 days in HIV‑negative patients with moderate‑to‑severe disease before any additional immunosuppressive therapy is considered.  [NCCN Guidelines 2017] 3
Clinical stability (afebrile, stable or improving oxygen requirement, and improving chest imaging) must be maintained for at least 7 days before acalabrutinib can be started. [NCCN Guidelines 2017] 4

Absolute neutrophil count (ANC) should be ≥500–1000 µL⁻¹ (ideally >1000 µL⁻¹) prior to acalabrutinib initiation to reduce the risk of compounded infection. [NCCN Guidelines 2020] 1
Growth‑factor support (e.g., G‑CSF) is recommended for persistent neutropenia until the target ANC is achieved. [NCCN Guidelines 2020] 1

Continue TMP‑SMX prophylaxis (single‑strength daily or double‑strength three times weekly) indefinitely while on acalabrutinib because of ongoing susceptibility to PJP. [NCCN Guidelines 2020] 1
Add antiviral prophylaxis (e.g., acyclovir) for herpes‑virus reactivation throughout acalabrutinib therapy. [NCCN Guidelines 2017] 4
Maintain prophylaxis until CD4⁺ T‑cell count exceeds 200 cells/mm³ for at least 2 months. [NCCN Guidelines 2017] 3

Delaying acalabrutinib by 2–3 weeks to ensure PJP cure does not materially affect lymphoma outcomes, given the typical median time to response of ~4 weeks with acalabrutinib. [NCCN Guidelines 2020] 6
Bendamustine‑based regimens cause profound CD4⁺ depletion and markedly increase PJP risk, supporting the need for lifelong PJP prophylaxis in this context. [Hematology‑Oncology Guidelines 2020] 2
Acalabrutinib demonstrates high efficacy in MCL (overall response rate 91–94 %, median progression‑free survival ≈66 months); however, infection control must precede therapy to avoid fatal complications. [NCCN Guidelines 2017] 3

Obtain a complete blood count weekly for the first month, then every 2–4 weeks to detect recurrent neutropenia or other cytopenias. [NCCN Guidelines 2020] 1
Vigilantly assess for new fever, respiratory symptoms, or other infections, adjusting therapy promptly if grade 3–4 neutropenia recurs. [NCCN Guidelines 2020] 1